1Y Close · As of Aug 26, 2026
HANS BIOMED operates in the Pharmaceuticals sector.
Legal name: HANS BIOMED CORPORATION
In fiscal year 2025, HANS BIOMED (042520) reported revenue of 89.8 billion KRW, up 10.7% from 81.1 billion KRW a year earlier.
Operating profit was -25.9 billion KRW and net income was -32.1 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 275.2 billion KRW, with a P/B of 8.12.
These figures can be verified in the DART filing (receipt no. 20251218000494).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 89.8B | -25.9B | -32.1B |
| 2024 | 81.1B | 626M | -7.8B |
| 2023 | 78.0B | -4.2B | -24.1B |
Recent Filings
Quarterly Report (2026.06)
Corporate Briefing (IR)
Large Shareholding Report (Simplified)
Checks
No items require attention at this time.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-13 | Quarterly Report (2026.06) |
| 2026-08-10 | Corporate Briefing (IR) |
| 2026-08-05 | Large Shareholding Report (Simplified) |